NCT07215650View on ClinicalTrials.gov

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

April 30, 2028

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

Cizutamig

Cizutamig will be dosed according to the protocol

Sponsors
All Listed Sponsors
lead

Candid Therapeutics

INDUSTRY